每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ 每经AI快讯，瑞普生物（SZ 300119，收盘价：19.18元）12月15日晚间发布公告称，公司第六届2025年 第六次董事会临时会议于2025年12月15日在公司会议室以现场会议方式召开。会议审议了《关于选举第 六届董事会董事长的议案》等文件。 2024年1至12月份，瑞普生物的营业收入构成为：兽用生物制品占比43.12%，兽用药物占比33.86%，宠 物供应链占比20.63%，其他占比2.38%。 截至发稿，瑞普生物市值为89亿元。 （记者 王晓波） ...

Core Viewpoint - Reap Bio announced the convening of its fifth board meeting to discuss amendments to the company's articles of association, indicating ongoing governance and strategic adjustments [1] Company Summary - Reap Bio's revenue composition for the year 2024 is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1] - As of the report, Reap Bio has a market capitalization of 9.2 billion yuan [1]

Core Viewpoint - Reap Bio announced the convening of its 29th temporary board meeting on October 24, 2025, to review the proposal for the Q3 2025 report [1] Company Summary - For the year 2024, Reap Bio's revenue composition is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1] - As of the report, Reap Bio's market capitalization stands at 9.7 billion yuan [1] Industry Summary - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion USD this year [1] - There is a contrast in the biopharmaceutical secondary market's activity compared to the primary market, where fundraising has encountered challenges [1]

Group 1 - The core point of the article is that Reap Bio (SZ 300119) held a temporary board meeting on October 13, 2025, to discuss investment proposals with professional investment institutions [1] - For the year 2024, Reap Bio's revenue composition is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chains, and 2.38% from other sources [1] - As of the report date, Reap Bio has a market capitalization of 10.2 billion yuan [1]

Group 1 - The core point of the article is that Reap Bio (SZ 300119) held a temporary board meeting on September 28, 2025, to discuss the proposal for the fifth temporary shareholders' meeting of 2025 [1] - For the year 2024, Reap Bio's revenue composition is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1] - As of the report date, Reap Bio has a market capitalization of 9.7 billion yuan [1] Group 2 - The article mentions a competitive scenario where Farmer's Green Bottle was launched, leading to a significant decline in market share for Yibao, dropping nearly 5 percentage points [1]

Group 1 - The core viewpoint of the article is that Reap Bio (SZ 300119) held its 26th meeting of the fifth board of directors on August 22, 2025, to review the agenda including the "2025 Semi-Annual Report" and its summary [1] - For the year 2024, the revenue composition of Reap Bio is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1]

Group 1 - The company, Reap Bio, announced a maximum guarantee of 15 million yuan for financing applications made by its subsidiaries to Industrial Bank Co., Ltd. Tianjin Branch, with a financing term of one year and a guarantee period of three years after the debt performance deadline [1] - As of the announcement date, the total guarantee amount provided by the company and its subsidiaries is approximately 247 million yuan, accounting for 5.54% of the company's latest audited net assets attributable to shareholders [1] - The cumulative external guarantee balance provided by the company and its subsidiaries is 90.16 million yuan, which also accounts for 2.02% of the company's latest audited net assets [1] Group 2 - For the year 2024, the revenue composition of Reap Bio is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [2] - The current market capitalization of Reap Bio is 10.9 billion yuan [2]

Group 1 - The company, Reap Bio, announced the convening of its 25th temporary board meeting on August 8, 2025, to discuss the proposal for the fourth temporary shareholders' meeting of 2025 [2] - For the year 2024, the revenue composition of Reap Bio is as follows: veterinary biological products account for 43.12%, veterinary drugs account for 33.86%, pet supply chain accounts for 20.63%, and others account for 2.38% [2]